From: Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers
AsPC-1
BxPc-3
Capan-1
MIA PaCa-2
PANC-1
K-ras
mut
wt
p53
nk
p16
-
P276-00
R
MS
Gemcitabine
S
G + P276-00 (CI)
MSy
HSy
WSy
(0.86-0.89)
(0.38-0.69)
(0.9-0.93)
(0.71-0.95)
(0.6-0.72)